Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting
Journal of Correctional Health Care · 01.12.2022 · 28 (6) · 368-371
DOI: 10.1089/jchc.21.07.0063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Correctional Health Care, erschienen am 01.12.2022. Verfasst von James S H Wong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Correctional Health Services, BC Mental Health and Substance Use Services, Provincial Health Services Authority, British Columbia, Canada. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Incarcerated clients experience high rates of opioid use disorder and overdose. It is critical that opioid agonist treatment (OAT) is provided in correctional facilities. However, few receive OAT due to concerns about diversion, misuse, and safety. Buprenorphine extended-release (BUP-XR), a monthly buprenorphine depot injection, could be especially advantageous in the correctional setting as it can prevent diversion and misuse, saving staff resources and time. An injection of BUP-XR is costly compared with a monthly supply of buprenorphine/naloxone (BUP/NX) tablets. We demonstrate that when factoring in the added costs of medication preparation, administration, monitoring, and personnel, it is more economical to provide BUP-XR than BUP/NX. Other facilities, by utilizing our cost breakdown, can determine whether BUP-XR is economically advantageous at their own facility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Correctional Health Services, BC Mental Health and Substance Use Services, Provincial Health Services Authority, British Columbia, Canada.
- Department of Psychiatry, University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada.
- Adult Custody Divisions, BC Corrections, Government of British Columbia, British Columbia, Canada.
ORCID-Profile: James S H Wong
Zitieren
APA
Wong, J. S. H., Masson, S., Huang, A., Romm, D., Fong, M., Porter, T., Sharifi, N., Azar, P., & Mathew, N. (2022). Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting. Journal of Correctional Health Care, 28(6), 368-371. https://doi.org/10.1089/jchc.21.07.0063
Vancouver
Wong JSH, Masson S, Huang A, Romm D, Fong M, Porter T, et al. Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting. Journal of Correctional Health Care. 2022;28(6):368-371. doi:10.1089/jchc.21.07.0063
BibTeX
@article{Wong2022,
author = {Wong, James S H and Masson, Sarah and Huang, Alan and Romm, Deanna and Fong, Maylene and Porter, Tony and Sharifi, Nader and Azar, Pouya and Mathew, Nickie},
title = {Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting},
journal = {Journal of Correctional Health Care},
year = {2022},
volume = {28},
number = {6},
pages = {368--371},
doi = {10.1089/jchc.21.07.0063}
}
EUVIMED